Top Markets
Coin of the day
AB Science S.A. AB Science S.A.

AB Science S.A.

AB
株式のランク #24476
AB Science S.A. is a pharmaceutical company dedicated to the discovery,... AB Science S.A. is a pharmaceutical company dedicated to the discovery, development, and commercialization of protein kinase inhibitors for applications in both human and animal health. Its primary drug candidate, masitinib, a tyrosine kinase inhibitor, is currently undergoing late-stage (Phase III) clinical investigations for a range of serious conditions including prostate cancer, pancreatic cancer, amyotrophic lateral sclerosis (ALS), multiple sclerosis, Alzheimer's disease, severe asthma, and mastocytosis. Additionally, masitinib is being evaluated in Phase II clinical trials for the treatment of Covid-19. The company's pipeline also features AB8939, a synthetic microtubule destabilizer aimed at treating acute myeloid leukemia, and AB20001, which is in Phase 2 trials to assess the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients experiencing moderate to severe COVID-19. Masitinib is sold under the brand name Masivet in the European market. AB Science S.A. was founded in 2001 and is based in Paris, France.
株価
$0.82200553
時価総額
$60.21M
変化(1日)
0.00%
変化(1年)
-45.55%
FR
取引 AB Science S.A. (AB)

カテゴリー

AB Science S.A.(AB)の株式分割履歴
AB Science S.A.株(シンボル:AB)は合計で0回の株式分割を実施しました。
最新の株式分割はAug 21, 2026に行われました。
Aug 21, 2026より前に購入されたAB株は、現在0AB株に相当します。
株式分割一覧
株式分割 分割比率 累積分割比率
提供された日付のデータは十分ではありません。
類似企業または競合他社の株式分割